Bristol Myers Sqibb (NYSE:BMY)
Historical Stock Chart
6 Months : From Nov 2018 to May 2019
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) on Monday said the European Commission approved the company's Sprycel in combination with chemotherapy for children with a form of leukemia.
The New York biopharmaceutical company said the approval covers the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia and includes both the tablet and powder formulations.
Bristol-Myers said the approval marks the second pediatric leukemia indication for Sprycel in Europe.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
February 11, 2019 07:32 ET (12:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.